| 0 | ℹ |
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).
(nature.com)
|
Nature Communications 2026-08-31 | #breast cancer #clinical trial #neoadjuvant #her2 #immunotherapy |